Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 0.46 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | SOD1 | P00441 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 4/20 | 0.39 |
| ▸ | AGXT | P21549 | 2/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20999089 | 0.88 | ESR1 (0.47) | IDO1TACR1MAOBAGXT | |
| SCHEMBL348504 | 0.86 | TACR1 (0.54) | IDO1TACR1MRGPRX4ACHEBCHE | |
| SCHEMBL20795882 | 0.85 | IDO1 (0.43) | IDO1TACR1MAOBAGXTKIF11 | |
| SCHEMBL26245888 | 0.85 | CYP4F2 (0.46) | IDO1MAOB | |
| SCHEMBL13252957 | 0.82 | TACR1 (0.45) | IDO1TACR1MRGPRX4ACHEBCHE | |
| SCHEMBL171782 | 0.82 | IDO1 (0.68) | IDO1MAOB | |
| SCHEMBL20795016 | 0.82 | ESR1 (0.50) | IDO1MAOB | |
| SCHEMBL4476728 | 0.82 | IDO1 (0.41) | IDO1TACR1MAOBAGXT | |
| SCHEMBL13798386 | 0.81 | TACR1 (0.50) | IDO1TACR1MRGPRX4ACHEBCHE | |
| SCHEMBL13547854 | 0.81 | TAAR1 (0.41) | IDO1TACR1ACHEBCHEHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411564-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2012-02-01 | — | — | EP | claimed |
| WO-2010108874-A1 | ELECTROCHEMICAL METHOD FOR PRODUCING 3 TERT.-BUTYL BENZALDEHYDE- DIMETHYLACETAL | BASF SE (DE) | 2010-09-30 | — | — | WO | claimed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | THE UNIVERSITY OF SUSSEX (GB) | 2023-11-09 | — | — | US | disclosed |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-05 | — | — | US | disclosed |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11530219-B2 | Ligands to cereblon (CRBN) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | BAYER HEALTHCARE LLC (US) | 2009-06-04 | — | — | US | disclosed |
| US-7429584-B2 | Furo[2.3-b]pyridine derivatives for the treatment of hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2008-09-30 | — | — | US | disclosed |
| US-7417053-B2 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2008-08-26 | — | — | US | disclosed |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-08-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | AERIE PHARMACEUTICALS, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072898-A1 | Pyrazolo[1,5-a]pyridine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAP4K2, MAPKAPK5 | IDO1 1737/4885TACR1 4727/4885MRGPRX4 1653/4885 |
| US-20090143412-A1 | FUROPYRIDINE AND FUROPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPER-PROLIFERATIVE DISORDERS | NCOR1, NR3C1, NR3C2 | IDO1 2168/4885TACR1 80/4885MRGPRX4 653/4885 |
| US-20230355617-A1 | SMALL MOLECULE INHIBITORS OF LEMUR TYROSINE KINASE 3 | LMTK3, LMTK2, LIMK1 | IDO1 1853/4885TACR1 4787/4885MRGPRX4 3674/4885 |
| US-20070254920-A1 | Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use | HCAR1, HCAR2, PAICS | IDO1 2912/4885TACR1 308/4885MRGPRX4 1055/4885 |
| US-20230312575-A1 | LIGANDS TO CEREBLON (CRBN) | CRBN, CRKL, CDR2 | IDO1 2998/4885TACR1 4336/4885MRGPRX4 1857/4885 |
| US-11530219-B2 | Ligands to cereblon (CRBN) | CRBN, CRKL, CDR2 | IDO1 2998/4885TACR1 4336/4885MRGPRX4 1857/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | IDO1 2567/4885TACR1 2238/4885MRGPRX4 1540/4885 |
| US-11701370-B2 | Phosphonium ion channel blockers and methods for use | TRPV1, TRPV5, TRPA1 | IDO1 1294/4885TACR1 193/4885MRGPRX4 201/4885 |
| US-11643404-B2 | Ester substituted ion channel blockers and methods for use | TRPV1, TRPA1, TRPV2 | IDO1 2739/4885TACR1 133/4885MRGPRX4 169/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | IDO1 1973/4885TACR1 3004/4885MRGPRX4 397/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | IDO1 2580/4885TACR1 1571/4885MRGPRX4 2219/4885 |
| US-20080194546-A1 | Pyrido-, Pyrazo- and Pyrimido-Pyrimidine Derivatives as mTOR Inhibitors | RPS6KB1, RPS6KA1, RPS3A | IDO1 2974/4885TACR1 4189/4885MRGPRX4 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.